Whalesbook
AI Aur Pharma Ka Maha Milan!
Scene yeh hai ki Novartis ke CEO, Vas Narasimhan, ab Anthropic ke board par aa gaye hain. Anthropic, woh AI company jiske peeche Claude jaise models hain, ab pharma mein bhi apna pair jama rahi hai. Is deal se AI ko seedha drug discovery aur development ke tough process mein integrate karne ki planning hai.
Anthropic ki valuation kya hai pata hai? Around $380 billion hai, February 2026 mein $30 billion ki Series G funding ke baad. Aur Novartis? Woh bhi koi choti company nahi, market cap $293 billion ke aas-paas hai. Is partnership se lagta hai Anthropic specialized industrial uses, khas kar drug discovery, par focus kar rahi hai. Aur Novartis bhi future ke liye AI ko ek game-changer maan rahi hai.
Dawaiyan Banane Ka Process Tez Hoga?
Experts ka kehna hai ki AI drug discovery ka market bhi rocket ki tarah badhne wala hai. Estimates hain ki yeh $6.89 billion se badhkar $43.9 billion tak ja sakta hai 2035 tak! Novartis apne share ko $154 ke aas-paas trade kar rahi hai, aur unka P/E ratio 21.4 hai. Woh AI ko sirf R&D tak nahi, balki poore operations mein integrate karna chahte hain. Goal hai 'develop better medicine faster'.
Vas Narasimhan ka background kaafi strong hai – medicine, global health, policy sab mein. Isse AI ko healthcare mein responsibly use karne mein help milegi. Novartis AI ko target identify karne, molecule design karne, aur especially clinical trials ko optimize karne mein use kar rahi hai, jisse development time kam se kam 6 mahine kam ho sakta hai. Woh OpenAI aur Isomorphic Labs jaise companies ke saath bhi jud gaye hain, dikha raha hai ki AI ko lekar inka vision kaafi broad hai.
Market Mein Kya Chal Raha Hai?
AI drug discovery mein competition bhi tight hai. Recursion Pharmaceuticals, Insilico Medicine jaise players bhi machine learning use kar rahe hain. Pfizer, Bayer, Eli Lilly jaise bade names bhi AI partnerships kar rahe hain. Eli Lilly ne toh NVIDIA ke saath bhi tie-up kiya hai.
Novartis ka P/E ratio 21.4 hai, jo unke 10-year median 20.11 se thoda upar hai. Brokerage analysts ki rai mili-juli hai, koi 'Hold' keh raha hai toh koi 'Moderate Buy'.
Kuch Challenges Bhi Hain
Lekin har chamakti cheez sona nahi hoti. Anthropic ki $380 billion ki valuation kaafi speculative hai, jo AI ke craze par zyada depend karti hai. Agar AI adoption slow hua toh valuation gir sakti hai. Aur Novartis ka P/E bhi market average 43.92 se kam hai, par unke historical averages se zyada hai.
Sabse important baat yeh hai ki AI se medicine development mein kitna real impact aata hai, woh dekhna hoga. Drugs ko patients tak pahunchne mein saalon lagte hain. Ethical concerns, data privacy, aur bias jaise issues bhi hain jinhe sambhalna hoga. US Department of Defense ne toh Anthropic ko 'supply chain risk' bhi bataya tha.
Aage Ka Kya Plan Hai?
Vas Narasimhan ka board join karna Novartis ka AI mein long-term commitment dikhata hai. Pharma industry jab AI ko use karegi toh regulations bhi strict hongi. Is partnership ki success Anthropic ki AI solutions aur Novartis ki unhe effectively use karne ki capacity par depend karegi.